Abstract: Objective To evaluate and summarize the experiences of the treatment of the patients with stage Ⅲ non-small cell lung cancer(NSCLC). Methods We reviewed a total of 188 cases treated with different methods, which included preoperative and postoperative chemotherapy combination with operation, operation combination with postoperative chemotherapy, simple operation and naive chemotherapy. Then the 1-year and 3-year survival rate and median survival time(MST) were analyzed and compared. The chemotherapy were all based on carboplatin combined with gemcitabin or taxol, but the preoperative received 2 or 3 cycle and postoperative received 4～6 cycle chemotherapy , and the naive chemotherapy also performed 4～6 cycle. Results The 1-year and 3-year survival rate of preoperative and postoperative chemotherapy combination with operation group exceeded the simple operation group significantly(P<0.01), but compared with postoperative chemotherapy combination with operation group the difference of 1-year survival rate was significantly(P<0.05) and that of 3-year was not evident(P>0.05). The resectability of preoperative and postoperative chemotherapy combination with operation group was better than that of postoperative chemotherapy combination with operation group(P<0.05). The 1-year survival rate of postoperative chemotherapy combination with operation group was improved compared with simple operation group but not statistically significant(P=0.069). As for naive chemotherapy group, there were no patients could live more than 3 years and the 1-year survival rate was the lowest among all groups. And its MST was only nine months less than preoperative and postoperative chemotherapy combination with operation group and postoperative chemotherapy combination with operation group evidently. Conclusion The patients with stage Ⅲ NSCLC would be received resection as possible even incomplete, and could had benefits from routine systematic hilar and mediastinal lymph node dissection. Postoperative chemotherapy might improved the survival rate. Neoadjuvant chemotherapy increased the resection rate and shown considerable improvement in survival time, but the effect of naive chemotherapy was disappointed.

Key words: non-small cell lung cancer, multi-modality treatment, survival rate